COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 1 of 3 for:    "Boehringer Ingelheim" AND "lupus"
Previous Study | Return to List | Next Study

Dose Finding, Efficacy and Safety of BI 655064 in Patients With Active Lupus Nephritis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02770170
Recruitment Status : Recruiting
First Posted : May 12, 2016
Last Update Posted : May 20, 2020
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:
The overall purpose of the study is to assess the efficacy of three different doses of BI 655064 against placebo as add-on therapy to standard of care (SOC) treatment for active lupus nephritis in order to characterize the dose-response relationship within the therapeutic range, and select the target dose for phase III development.

Condition or disease Intervention/treatment Phase
Lupus Nephritis Drug: BI 655064 dose 1 Drug: BI 655064 dose 2 Drug: BI 655064 dose 3 Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Double-blind, Randomised, Placebo-controlled Trial Evaluating the Effect of BI 655064 Administered as Sub-cutaneous Injections, on Renal Response After One Year of Treatment, in Patients With Active Lupus Nephritis
Actual Study Start Date : May 16, 2016
Estimated Primary Completion Date : June 30, 2020
Estimated Study Completion Date : August 30, 2020

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: BI 655064 dose 1 Drug: BI 655064 dose 1
Experimental: BI 655064 dose 2 Drug: BI 655064 dose 2
Experimental: BI 655064 dose 3 Drug: BI 655064 dose 3
Placebo Comparator: Placebo Drug: Placebo

Primary Outcome Measures :
  1. Proportion of patients with complete renal response [ Time Frame: week 52 ]

Secondary Outcome Measures :
  1. Proportion of patients with complete renal response [ Time Frame: week 26 ]
  2. Proportion of patients with partial renal response [ Time Frame: week 26 and 52 ]
  3. Proportion of patients with major renal response [ Time Frame: week 26 and 52 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Males and females 18-70 years. Women of childbearing potential must be ready and able (as assessed by investigator) to use simultaneously two reliable methods of birth control, one of which must be highly effective. Highly effective method, per ICH M3(R2) is a method that result in a low failure rate of less than 1% per year when used consistently and correctly.
  • Diagnosis of systemic lupus erythematosus (SLE) by American College of Rheumatology (ACR) criteria 1997, at least 4 criteria must be documented, one of which must be a positive anti-dsDNA antibody OR a positive antinuclear antibody (ANA) at screening or around time of start of induction therapy
  • Lupus Nephritis Class III or IV (International Society of Nephrology (ISN)/Renal Pathology Society (RPS) -2003 classification) with either active or active/chronic disease, co-existing class V permitted, proven by renal biopsy within 3 months prior to screening or during screening if induction therapy has not yet been started
  • Active renal disease evidenced by proteinuria ≥ 1.0 g/day [(Uprot/Ucrea) ≥ 1]
  • Signed and dated written informed consent

Exclusion criteria:

  • Clinically significant current other renal disease
  • Glomerular Filtration Rate <30ml/min/1.73m²
  • Dialysis within 12m of screening
  • Antiphospholipid syndrome
  • Diabetes mellitus poorly controlled or known diabetic retinopathy or nephropathy
  • Evidence of current or previous clinically significant disease, medical condition or finding in the medical examination that in the investigator's opinion would compromise the safety of the patient or the quality of the data
  • Any induction therapy for Lupus Nephritis within the last 6 months prior to randomisation except induction with Mycophenolate Mofetil and high dose steroids started within 6 weeks prior to randomisation

    • Treatment with any biologic B-cell depleting therapy (e.g. anti-CD20, anti-CD22,) within 12 months prior to randomisation
    • Treatment with abatacept within 12 months prior to randomisation
    • Treatment with tacrolimus or cyclosporin within 4 weeks prior to randomisation
    • Treatment with cyclophosphamid within 6 months prior to randomisation
    • Treatment with investigational drug within 6 months or 5 half-lives, whichever is greater before randomisation
  • Contraindication for MMF or corticosteroids and/or known hypersensitivity to any constituents of the study drug.
  • Chronic or relevant acute infections, including but not limited to HIV, Hepatitis B and C and tuberculosis (including a history of clinical tuberculosis (TB) and/or a positive QuantiFERON TB-Gold test
  • Any active or suspected malignancy or history of documented malignancy within the last 5 years before screening, except appropriately treated carcinoma in situ and treated basal cell carcinoma.
  • Live vaccination within 6 weeks before randomisation
  • Patients unable to comply with the protocol in the investigator's opinion.
  • Alcohol abuse in the opinion of the investigator or active drug abuse .
  • Women who are pregnant, nursing, or who plan to become pregnant while in the trial
  • Impaired hepatic function, defined as serum Aspartate Transferase/Alanine Transferase, bilirubin or alkaline phosphatase levels > 2 x Upper Limit of Normal
  • Further exclusion criteria apply.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02770170

Layout table for location contacts
Contact: Boehringer Ingelheim Call Center 1-800-243-0127

Show Show 75 study locations
Sponsors and Collaborators
Boehringer Ingelheim
Layout table for investigator information
Study Chair: Boehringer Ingelheim Boehringer Ingelheim

Layout table for additonal information
Responsible Party: Boehringer Ingelheim Identifier: NCT02770170    
Other Study ID Numbers: 1293.10
2015-001750-15 ( EudraCT Number )
First Posted: May 12, 2016    Key Record Dates
Last Update Posted: May 20, 2020
Last Verified: May 2020
Additional relevant MeSH terms:
Layout table for MeSH terms
Lupus Nephritis
Kidney Diseases
Urologic Diseases
Lupus Erythematosus, Systemic
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases